Article Text

Download PDFPDF
Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review
  1. Lidia Rosi Medeiros, MD, PhD*,
  2. Daniela Dornelles Rosa, MD, PhD,
  3. Maria Inês Da Rosa, MD, PhD*,,
  4. Mary Clarisse Bozzetti, MD, PhD*,,§ and
  5. Roselaine Ruviaro Zanini, PhD*,
  1. *Federal University of Rio Grande do Sul; and
  2. Hospital Fêmina and Hospital Moinhos deVento, Porto Alegre;
  3. University of Extremo Sul Catarinense, Criciúma;
  4. §Department of Social Medicine, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre; and
  5. Department of Statistics, Federal University of Santa Maria, Santa Maria,Brazil.
  1. Address correspondence and reprint requests to Lidia Rosi Medeiros, MD, PhD, José de Alencar 1244 apt 1009, Porto Alegre, RS, Brasil, CEP 90880-480. E-mail: lidia.rosi{at}


Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide. Two vaccines have been recently evaluated in randomized controlled trials: the bivalent vaccine for HPV 16 and 18 (Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and the quadrivalent vaccine for HPV 6, 11, 16, and 18 (Gardasil, Merck and Co, Inc, Whitehouse Station, NJ). We have performed a systematic review of all randomized controlled trials in which vaccines against HPV were compared with placebo regarding efficacy, safety, and immunogenicity. Six studies met the inclusion criteria, which included 47,236 women. The first objective in this systematic review was to assess vaccine efficacy in the prevention of cytologically and/or histologically proven lesions. And the secondary objective was the evaluation of safety and vaccine immunogenicity. Bivalent and quadrivalent HPV vaccines significantly reduced the rate of lesions in the cervix, vulva, vagina, and anogenital region, with efficacy of 93% (95% confidence interval [CI], 87-96) and 62% (95% CI, 27-70), respectively, when compared with the control groups according to intention to treat. Regarding safety, we found more symptoms in the bivalent vaccine group (35%; 95% CI, 5-73) when compared with the control groups. In regard to vaccine immunogenicity, there was seroconversion in the group that received the vaccine when compared with the placebo group in the bivalent and quadrivalent vaccines. Prophylactic vaccination can prevent HPV infection in women aged 9 to 26 years not previously infected with the HPV subtypes covered by the vaccines. To evaluate cervical cancer incidence and mortality, a longer follow-up is necessary.

  • HPV
  • Vaccine
  • Cervical intraepithelial neoplasia
  • Meta-analysis
  • Systematic review

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.

  • Dr. Medeiros had full access to all data and take responsibility for the integrity and the accuracy of the analysis. Dr. Rosa, Dr. da Rosa, and Dr. Bozzetti organized the study concept and the design. Dr. Zanini acquired, analyzed, and interpreted the data. All authors drafted the manuscript. Dr. Medeiros and Dr. Zanini performed the statistical analysis.